Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOSES study of DOAC-guided secondary stroke prevention
2019-002404-41Phase 3Active
- Sponsor
- Mira Katan
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban and dabigatran in ischemic stroke (2 arms), sponsored by Mira Katan. Started May 2022; status: active.
02
Drugs
apixabandabigatran
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2019-002404-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002404-41.